$MIRM Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.87 down -1840.00% YoY
• Reported revenue of $185.72M up 39.63% YoY
• Mirum expects total product sales of approved medicines to continue to increase on an annual basis and anticipates net losses for the foreseeable future; no quantified financial range was provided.